Inhibiting CK2α from Outside the Active Site
Poster Mar 03, 2017
Paul Brear[sup]1[/sup], Claudia De-Fusco[sup]2[/sup], Kathy Hadje Georgiou[sup]2[/sup], Nicola J. Francis-Newton[sup]3[/sup], Chris Stubbs[sup]2[/sup], Ashok R. Venkitaraman[sup]3[/sup], Chris Abell[sup]2[/sup], David Spring[sup]2[/sup], Marko Hyvonen[sup]1[/sup]
EKJ is a highly conserved kinase with pro survival and anti-apoptotic effects on cells. It is often overexpressed in cancer cells in which it promotes their proliferation by multiple mechanisms. A number of potent CK2a inhibitors,B that target only the ATP site, have been shown to inhibit the growth of a range of cancer cell lines and one of these, CX-4945 has progressed to phase II clinical trials. Although described as highly selective, CX-4945 inhibits at least 12 other kinases with nanomolar IC50's.
Strategies to inhibit CK2a without targeting the ATP binding site offer the promise of enhanced selectivity as well as new mechanisms of action. Here we report the creation and characterization of a unique inhibitor of CK2a that targets a novel cryptic pocket and was developed using fragment-based methods.
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
MicroRNAs as Bile-Based Biomarkers in Pancreatic Cancer and Biliary Tract CancersPoster
In this study, the role of miRNAs has been assessed in a large cohort of pancreatic cancer.READ MORE
Is Oxford Nanopore Technology Ready for Clinical Diagnostics?Poster
Our objective is to validate diagnostic services using Oxford Nanopore’s Minion in the first instance and to evaluate the cost and performance compared to existing sequencing technology in areas such as tumour DNA sequencing (and circulating tumour DNA), virology, microbiology, genetics and HLA-typing.READ MORE
Comments | 0 ADD COMMENT
Outsourcing in Clinical Trials Southern California
Sep 27 - Sep 28, 2017